Inicio › Linfoma de Burkitt › Texas
Ensayos clínicos de Linfoma de Burkitt en Texas
24 estudios sobre Linfoma de Burkitt buscan participantes en Texas.
Ciudades en Texas
- Houston21 estudios
- San Antonio7 estudios
- Dallas7 estudios
- Austin5 estudios
- Fort Worth4 estudios
- Corpus Christi4 estudios
- El Paso4 estudios
- Killeen3 estudios
- Lubbock3 estudios
Texto oficial del estudio (inglés)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- y 10 más
ReclutandoFase 2
366 Days – 46 Years · Todos los sexos · Actualizado el 28 sept 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- y 7 más
ReclutandoFase 2
365 Days · Todos los sexos · Actualizado el 25 sept 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT07648264Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
ReclutandoFase 1/2
6 Months – 25 Years · Todos los sexos · Actualizado el 17 sept 2026 · NCT06395103A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Baylor College Medical Center (Data Collection Only), Houston
- Texas Children's Hospital (Data Collection), Houston
ReclutandoFase 3
Edades de 1 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07223021A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Methodist Children's Hospital, San Antonio
ReclutandoFase 1
Edades de 0 a 18 · Todos los sexos · Actualizado el 16 sept 2026 · NCT06173518Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Baylor University Medical Center, Dallas
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT03666000Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Houston Methodist Hospital, Houston
ReclutandoFase 3
Edades de 18 a 39 · Todos los sexos · Actualizado el 2 sept 2026 · NCT03150693A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- y 10 más
ReclutandoFase 2
Edades de 1 a 30 · Todos los sexos · Actualizado el 1 sept 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- y 12 más
ReclutandoFase 3
365 Days – 25 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03959085AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Houston
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT06137118Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- University of Texas, Southwestern, Dallas
- Baylor Texas Children's Hospital, Houston
ReclutandoFase 2
Edades de 7 a 25 · Todos los sexos · Actualizado el 19 ago 2026 · NCT05082519Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
- MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 ago 2026 · NCT06287229Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- M D Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 15 en adelante · Todos los sexos · Actualizado el 10 ago 2026 · NCT03136146Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 13 a 90 · Todos los sexos · Actualizado el 6 ago 2026 · NCT06533579Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- M D Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 jul 2026 · NCT01371630Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Houston
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 13 jul 2026 · NCT07109219Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
ReclutandoEstudio observacional
Edades de 0 a 38 · Todos los sexos · Actualizado el 4 jun 2026 · NCT06131801Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
- M D Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 14 en adelante · Todos los sexos · Actualizado el 20 may 2026 · NCT02877303Study of SGR-1505 in Mature B-Cell Neoplasms
- University of Texas Southwestern, Dallas
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2025 · NCT04260022Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Sarah Cannon - St. David's South Austin Medical Center, Austin
- MD Anderson Cancer Center, Houston
- Sarah Cannon - Texas Transplant Institute at Methodist Hospital, San Antonio
ReclutandoFase 1/2
Edades de 15 a 50 · Todos los sexos · Actualizado el 9 sept 2025 · NCT04150497The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- The University of Texas M. D. Anderson Cancer Center, Houston
- Methodist Healthcare System, San Antonio
ReclutandoFase 2
Edades de 1 a 25 · Todos los sexos · Actualizado el 4 may 2025 · NCT03509961Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 nov 2024 · NCT06034275De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.